JAKPOT Study - Adult Arm

STUDY BASICS

Were you recently diagnosed with type 1 diabetes? Are you 18-35 years old? You may be eligible for a research study to see if two inhibitors can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D). Compensation is provided.

STUDY PURPOSE

TrialNet is testing two different Janus kinase (JAK) inhibitors to see if either or both can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D). 

COULD THIS STUDY BE RIGHT FOR YOU?

Eligible participants:

• Are ages 18-35
• Are newly diagnosed with T1D (in past 3 months)

WHAT PARTICIPANTS CAN EXPECT

The two JAK inhibitors being tested in this study are abrocitinib and ritlecitinib. To understand which treatment works best, participants will be randomly assigned to one of three groups: one group will get abrocitinib, one will get ritlecitinib, and one will get a matching placebo (looks like the study treatment but has no active ingredients). 

Participants will be followed for two years. The first year will be the treatment phase and will involve scheduled monitoring visits, and some visits include mixed meal tolerance tests (MMTT). The second year will involve two visits—at 18 and 24 months—where mixed meal tolerance tests (MMTT) will also be performed.